Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2297552 | 0.85 | TDP1 (0.66) | MAPTTDP1HDAC6HDAC1HDAC8 | |
| SCHEMBL2635910 | 0.85 | HDAC6 (0.62) | MAPTTDP1HDAC6HDAC1HDAC8 | |
| SCHEMBL4809042 | 0.85 | MAPT (0.66) | MAPTTDP1HDAC6HDAC1 | |
| Hydrochloric Acid SCHEMBL3176039 | 0.83 | TDP1 (0.63) | MAPTTDP1HDAC6HDAC1HDAC8 | |
| SCHEMBL28869687 | 0.82 | HDAC6 (0.69) | HDAC6HDAC1HDAC8HDAC2 | |
| SCHEMBL2945096 | 0.82 | HDAC6 (0.69) | HDAC6HDAC1HDAC8HDAC2 | |
| SCHEMBL649380 | 0.81 | MAPT (0.61) | MAPTTDP1HDAC6HDAC1HDAC8 | |
| SCHEMBL10634169 | 0.81 | MAPT (0.61) | MAPTTDP1 | |
| SCHEMBL3250190 | 0.80 | MAPT (0.59) | MAPTTDP1 | |
| Hydrochloric Acid SCHEMBL1416999 | 0.80 | MAPT (0.59) | MAPTTDP1HDAC6HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461010-A2 | HYDROXAMIC ACID AND ITS DERIVATIVES AS INHIBITORS OF MELANOCYTE TYROSINASE FOR TOPICAL SKIN LIGHTENERS | Integriderm, Inc. (US) | 2004-09-29 | — | — | EP | claimed |
| US-20030199558-A1 | Hydroxamic acid and its derivatives as inhibitors of melanocyte tyrosinase for topical skin lighteners | INTEGRIDERM, INC. | 2003-10-23 | — | — | US | claimed |
| WO-2003057184-A2 | HYDROXAMIC ACID AND ITS DERIVATIVES AS INHIBITORS OF MELANOCYTE TYROSINASE FOR TOPICAL SKIN LIGHTENERS | INTEGRIDERM, INC. (US) | 2003-07-17 | — | — | WO | claimed |
| EP-1461010-A2 | HYDROXAMIC ACID AND ITS DERIVATIVES AS INHIBITORS OF MELANOCYTE TYROSINASE FOR TOPICAL SKIN LIGHTENERS | Integriderm, Inc. (US) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003057184-A2 | HYDROXAMIC ACID AND ITS DERIVATIVES AS INHIBITORS OF MELANOCYTE TYROSINASE FOR TOPICAL SKIN LIGHTENERS | INTEGRIDERM, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199558-A1 | Hydroxamic acid and its derivatives as inhibitors of melanocyte tyrosinase for topical skin lighteners | TYR, MC1R, MITF | MAPT 1674/4885TDP1 2112/4885HDAC6 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.